Clinigen Issue of Equity

3rd November 2021

Issue of Equity

Clinigen Group plc (AIM: CLIN, the "Group") announces that it has made an application for the admission to trading on AIM of 338,079 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"). These New Ordinary Shares have been issued to satisfy share options vesting under the 2018 Clinigen Group Long-Term Incentive Plan and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 4 November 2021.

At admission the issued share capital of the Group will consist of 133,366,726 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 133,366,726. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.

-Ends-

Contact details

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 120 countries.

For more information on Clinigen, please visit http://www.clinigen.com